The R/S is successful because they have great science and significant competitive advantages with PolyStart, the original TAP technology and the access to the Mayo antigens through the collaboration with Keith Knutson. Our relationship with Keith is a huge advantage for the future. The combination of all of these unique assets makes us special and sought after.
A capital raise in my opinion will actually propel the price even higher as we go over $5 per share, more blue chip, life science institutional investors will want to pile in. The time is right for immunotherapy companies and the apetite for revolutionary biotech investments is strong.
Nice to read in the shareholder letter that PolyStart could become a
platform that creates many revenue generation opportunities.
News 
Market Data 
Discover 
AI
